3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
3
Completed
2
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
10
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Lymphoid
1
Conditions
Neoplasms
1905
Breast Neoplasms
1426
Carcinoma, Non-Small-Cell Lung
1179
Prostatic Neoplasms
740
Colorectal Neoplasms
686
Neoplasm Metastasis
624
Multiple Myeloma
548
Melanoma
529
Ovarian Neoplasms
456
Lung Neoplasms
447
Lymphoma, Non-Hodgkin
385
Recurrence
374
Lymphoma
374
Leukemia, Myeloid, Acute
370
Pancreatic Neoplasms
358
Carcinoma, Renal Cell
339
Carcinoma, Hepatocellular
286
Stomach Neoplasms
281
Leukemia, Lymphocytic, Chronic, B-Cell
268
Lymphoma, Follicular
254
Head and Neck Neoplasms
246
Glioblastoma
220
Leukemia
215
Small Cell Lung Carcinoma
183
Lymphoma, Large B-Cell, Diffuse
183
Squamous Cell Carcinoma of Head and Neck
181
Urinary Bladder Neoplasms
175
Carcinoma
175
Uterine Cervical Neoplasms
174
Advanced Solid Tumors
161
Interventions
iron isomaltoside 1000
1
ferric carboxymaltose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Anemia, Iron-Deficiency
×
Clear all
NCT04318405
2023-07-19
Real-CHOICE
Pierre Fabre Pharma AG
Completed
327 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled